• Pliant Receives FDA Orphan Drug Designation for PLN-74809 fiercebiotech
    August 07, 2018
    Pliant Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's anti-fibrotic lead compound, PLN-74809, for the treatment of idiopathic pulmonary fibrosis (IPF).
PharmaSources Customer Service